CARDIOPROGRESS
Foundation for the advancement of cardiology

Heart Disease Risk May Start Before Birth A woman's prepregnancy heart health is critical to both her health as well as the health of the children she gives birth to, according to researchers.

Cancer survivors may be at heightened risk of cardiovascular disease An international clinical trial testing statin therapy for primary cardiovascular prevention in people living with HIV has been stopped early due to strong evidence of efficacy and safety in this population.

High Biomarker Level Plus Diabetes Predict Bad PCI Outcomes Among patients with type 2 diabetes and coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI), those with a high platelet-to-lymphocyte ratio (PLR) at the time of their procedure had a significantly higher risk for major adverse cardiovascular and cerebrovascular events (MACCE) and stent thrombosis compared with similar patients with a low PLR during a median 2.4-year follow-up. Patients with PCI and a high PLR, but without type 2 diabetes, were not at increased risk for these outcomes compared with similar patients with a low PLR.

Dabigatran Recalled Over Potential Carcinogen Ascend Laboratories LLC is recalling 10 lots of the oral anticoagulant dabigatran etexilate capsules (75 mg and 150 mg) because of unacceptable levels of a potential carcinogen.

Treat to LDL Target or High-Intensity Statin for All With Clinical CAD: LODESTAR How secondary prevention statins are given to push LDL cholesterol levels lower, whether in a high-intensity statin regimen or by dosage titration to meet LDL targets, may make little difference to clinical outcomes, suggests a randomized trial.

Sports-Related Sudden Cardiac Arrest 'Extremely' Rare in Women Sports-related sudden cardiac arrest (Sr-SCA) appears to be extremely rare in women compared with men, despite similar characteristics and circumstances of occurrence, data from three European population-based registries suggest.

Oral PCSK9 Inhibitor Shows Encouraging LDL Lowering A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug in development by Merck has shown encouraging results in a phase 2 study. The study was presented by Christie Ballantyne, MD, Baylor College of Medicine, Houston, Texas at the recent American College of Cardiology (ACC) Scientific Session/World Congress of Cardiology (WCC) 2023.

Cardiovascular Risk Factors Rife in Argentine Cardiologists Despite cardiologists' knowledge about cardiovascular disease and risk factors, they have a high prevalence of these risk factors. This observation suggests poor working conditions for cardiologists of both sexes and a high prevalence of workplace gender violence for female cardiologists, according to a study conducted by the Argentine Society of Cardiology (SAC).

New Tool Better Estimates Cardiovascular Risk in People With Lupus A tool that incorporates lupus-related variables with traditional risk factors provides a much more accurate assessment of cardiovascular (CV) risk in patients with systemic lupus erythematosus (SLE), according to data presented at the annual meeting of the Canadian Rheumatology Association.

Dapagliflozin Gets Expanded Heart Failure Indication in Europe The European Commission (EC) has expanded the indication for dapagliflozin (Forxiga) to include heart failure (HF) across the full spectrum of left ventricular ejection fraction — including HF with mildly reduced and preserved ejection fraction, AstraZeneca has announced.

The New Playbook for Ditching Dangerous Senior Meds A new tool presented at the American Geriatrics Society (AGS) 2025 Annual Scientific Meeting may give clinicians practical and safer alternatives to risky medications for patients.

International Research in Cardiology 2010-2014 Dear colleagues!
The Cardioprogress Foundation presents the book «International Research in Cardiology», which includes the results of the most important international clinical trials presented in 2010-2024. The authors systematized studies in 21 sections, which include risk factors, antiplatelet and anticoagulant therapy, laboratory and instrumental diagnostics, arrhythmia, invasive cardiology, valvular heart diseases, intensive care in cardiology and more.

Lowering BP According to Newest Guidance Would Cut CV Events Using the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guideline target of systolic blood pressure (BP) < 120 mm Hg, 66% of adults with chronic kidney disease (CKD) would be eligible for BP lowering, according to a study from South Korea.

Distress-Related Metabolite Levels Predicts Future Cardiovascular Events A metabolite-based distress score derived from measurements of molecular biomarkers in women related to chronic distress can predict future risk for cardiovascular disease. The study covered in this summary was published in medRxiv.org as a preprint and has not yet been peer reviewed.

Ending Rheumatic Heart Disease is achievable if we put our heads and minds to it Preventable, yet persistent, Rheumatic Heart Disease (RHD) is the most commonly acquired heart disease in people under 25 years of age. The World Heart Federation (WHF) is committed to the fight to ensure cardiovascular health for everyone. Through WHF’s network of Members and the power of personal testimonials, we are spreading awareness that RHD can be prevented, diagnosed, and treated. This editorial was authored by WHF Director of Policy and Advocacy Jeremiah Mwangi and was first published in FORESIGHT Global Health on 19 August 2021.

Dear colleagues! I welcome you on behalf of the Organizing Committee of the XI International Forum for Cardiology and Internal Medicine, which will be held from March 22 to 24, 2022 in Moscow.

Polypill Shows LDL-Lowering Advantage in High-risk Primary Prevention Patients: VULCANO Key Takeaways The CNIC (Centro Nacional de Investigaciones Cardiovasculares) polypill contains acetylsalicylic acid (100 mg), atorvastatin (30 mg or 40 mg), and ramipril (2.5 mg, 5 mg, or 10 mg), and is the only polypill for cardiovascular disease (CVD) currently marketed in European countries.

Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health.

The Scientific Committee begins accepting abstracts and applications for the scientific program of the XI International Forum of Cardiology and Internal Medicine Dear Colleagues! We invite you to take part in XI International Forum of Cardiology and Internal Medicine. Forum will take place on 22-24 March 2022 in Moscow (online).

Analysis of the activities of the "Cardioprogress" foundation: results of 2021 Dear colleagues! In 2021, a number of significant events took place in cardiology. Due to the continuation of restrictive measures, most scientific events were organized online. This required adaptation and the acquisition of new skills. However, all planned events took place.